Search Within

Matthew J Matasar

  1. "Population Sciences Research Program"
  2. "Sloan Kettering Institute Postdocs"
  3. "Andrew Intlekofer"
  4. "Andrew Zelenetz"
  5. "Helen Hancock"
  6. "Joachim Yahalom"
  7. "Maria Palomba"
Formats
  1. Meeting Abstract (3)
  2. Journal Article (1)
Groups
  1. Advanced Practice Providers (4)
  2. Bone Marrow Transplant (4)
  3. Center for Hematologic Malignancies (4)
  4. Department of Medicine (4)
  5. GSK Faculty (4)
  6. Hematologic Malignancies Research (4)

More Groups

People
  1. Alison Moskowitz (4)
  2. Andrew Intlekofer (4)
  3. Andrew Zelenetz (4)
  4. Anita Kumar (4)
  5. Ariela Noy (4)
  6. Audrey Hamilton (4)

More People

Years
  1. 2022 (1)
  2. 2021 (1)
  3. 2020 (1)
  4. 2019 (1)
Publications
  1. Blood (3)
  2. Journal of Clinical Oncology (1)
Publishers
  1. American Society of Hematology (3)
  2. American Society of Clinical Oncology (1)

Results (4)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save